Ocugen (OCGN) Accumulated Expenses (2014 - 2026)
Ocugen (OCGN) reported Accumulated Expenses of $11.6 million for Q1 2026, down 10.17% on a YoY basis from $12.9 million in Q1 2025, and down 21.18% quarter-over-quarter from $14.7 million in Q4 2025.
Ocugen (OCGN) Accumulated Expenses (2014 - 2026) Analysis & Trends
Ocugen has reported Accumulated Expenses for 13 years, with the latest figure at $11.6 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses fell 10.17% year-over-year to $11.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (down 10.17% YoY), and the FY2025 full-year result was $14.7 million, down 4.95% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $11.6 million, down from $14.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $20.0 million in Q4 2022, with the low at $9.2 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $14.3 million across 5 years, with a median of $13.3 million in 2023.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 361.76% — and 2023, when it plunged 33.19%.
- Ocugen's Accumulated Expenses stood at $20.0 million in 2022, then sank by 33.19% to $13.3 million in 2023, then gained by 16.17% to $15.5 million in 2024, then declined by 4.95% to $14.7 million in 2025, then decreased by 21.18% to $11.6 million in 2026.
- The last three Accumulated Expenses figures came in at $11.6 million (Q1 2026), $14.7 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.61 Mn |
| Dec 31, 2025 | 14.73 Mn |
| Sep 30, 2025 | 14.93 Mn |
| Jun 30, 2025 | 12.90 Mn |
| Mar 31, 2025 | 12.93 Mn |
| Dec 31, 2024 | 15.50 Mn |
| Sep 30, 2024 | 12.48 Mn |
| Jun 30, 2024 | 12.81 Mn |
| Mar 31, 2024 | 12.43 Mn |
| Dec 31, 2023 | 13.34 Mn |
| Sep 30, 2023 | 14.99 Mn |
| Jun 30, 2023 | 18.83 Mn |
| Mar 31, 2023 | 16.72 Mn |
| Dec 31, 2022 | 19.97 Mn |
| Sep 30, 2022 | 17.62 Mn |
| Jun 30, 2022 | 11.73 Mn |
| Mar 31, 2022 | 9.15 Mn |
| Dec 31, 2021 | 4.33 Mn |
| Sep 30, 2021 | 3.96 Mn |
| Jun 30, 2021 | 3.87 Mn |